Integra Lifesciences(DE:IL3)
€12.60+0.70 (+0.80%)
DE:IL3
Integra Lifesciences ownership
€12.60
At close:+0.70 (+0.80%)
Integra Lifesciences (IL3) Ownership - Who Owns Integra Lifesciences?
0 Followers
Integra Lifesciences (IL3) Ownership Overview
- 3.26% Insiders
- 30.35% Mutual Funds
- 2.69% Other Institutional Investors
- 29.84% ETFs
- 33.87% Public Companies and Individual Investors
The ownership structure of Integra Lifesciences (DE:IL3) stock is a mix of institutional, retail, and individual investors. Approximately 62.88% of the company’s stock is owned by Institutional Investors, 3.26% is owned by Insiders, and 33.87% is owned by Public Companies and Individual Investors.
The ownership structure of Integra Lifesciences (DE:IL3) stock is a mix of institutional, retail, and individual investors. Approximately 62.88% of the company’s stock is owned by Institutional Investors, 3.26% is owned by Insiders, and 33.87% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Nov 05, 2025 | Jeffrey Graves | $102,150 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Deerfield Management Company, Lp | €486,975 | |
| Dec 31, 2025 | Moore Capital Management Lp | €662,358 | |
| Dec 31, 2025 | Olstein Capital Management, L.p. | €1,527,660 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 10,684,103 | Institution | 13.73% | 149,374,444 |
| Ishares | 10,106,265 | Institution | 12.99% | 141,295,691 |
| Vanguard | 6,592,559 | Institution | 8.47% | 92,170,567 |
| Vanguard Index Funds | 5,353,918 | Institution | 6.88% | 74,853,128 |
| Aim Sector Funds (invesco Sector Funds) | 3,389,024 | Institution | 4.36% | 47,381,945 |
| Undiscovered Managers Funds | 2,822,343 | Institution | 3.63% | 39,459,177 |
| Dfa | 2,154,949 | Institution | 2.77% | 30,128,342 |
| Stuart Essig | 1,785,271 | Insider | 2.29% | 24,959,874 |
| Spdr | 1,424,368 | Institution | 1.83% | 19,914,089 |
| Dfa Investment Dimensions Group Inc | 1,253,270 | Institution | 1.61% | 17,521,968 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 5,353,918 | Institution | 6.88% | 74,853,128 |
| Aim Sector Funds (invesco Sector Funds) | 3,389,024 | Institution | 4.36% | 47,381,945 |
| Undiscovered Managers Funds | 2,822,343 | Institution | 3.63% | 39,459,177 |
| Dfa Investment Dimensions Group Inc | 1,253,270 | Institution | 1.61% | 17,521,968 |
| Neuberger Berman Equity Funds | 1,047,934 | Institution | 1.35% | 14,651,165 |
| Vanguard Scottsdale Funds | 909,653 | Institution | 1.17% | 12,717,859 |
| Fidelity Salem Street Trust | 853,808 | Institution | 1.10% | 11,937,090 |
| Glenmede Fund Inc | 842,751 | Institution | 1.08% | 11,782,502 |
| Capitol Series Trust | 796,433 | Institution | 1.02% | 11,134,930 |
| Northern Lights Fund Trust Ii | 735,660 | Institution | 0.95% | 10,285,262 |
FAQ
Who Owns Integra Lifesciences (DE:IL3)?
According to the latest TipRanks data, approximately 62.88% of the company's stock is held by institutional investors, 3.26% is held by insiders, and 33.87% is held by public companies and individual investors.
What percentage of Integra Lifesciences (DE:IL3) stock is held by institutional investors?
According to the latest TipRanks data, approximately 62.88% of Integra Lifesciences (DE:IL3) stock is held by institutional investors: 30.35% by mutual funds, 29.84% by ETFs and 2.69% by other institutional investors.
What percentage of Integra Lifesciences (DE:IL3) stock is held by retail investors?
According to the latest TipRanks data, approximately 33.87% of Integra Lifesciences (DE:IL3) stock is held by public companies and individual investors.
Who owns the most shares of Integra Lifesciences (DE:IL3)?
BlackRock, Inc. owns the most shares of Integra Lifesciences (DE:IL3).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
